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Abstract
Background: Some epidemiological, genetic, and experimental data suggest a possible role of vitamin D in the
pathogenesis of multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis. Data on the possible
contribution of several single nucleotide polymorphisms (SNP) in the vitamin D receptor (VDR) gene to the risk for MS are
controversial. Several studies suggested an interaction between some SNPs in the VDR gene and HLADRB1*1501 in the risk
for MS.
Objectives: The aim of this study was to investigate a possible influence of the SNPs rs2228570 and rs731236 in the VDR
gene in the risk for MS. A secondary objective was to address the possible interactions between VDR genes and
HLADRB1*1501.
Methods: We analyzed the allelic and genotype frequency of VDR rs2228570, rs731236, and HLADRB1*1501 (rs3135388) in
303 patients with MS and 310 healthy controls, using TaqMan Assays. We also conducted a meta-analysis, that was carried
out by using the software Meta-Disc 1.1.1 (http://www.hrc.es/investigacion/metadisc.html; Unit of Clinical Statistics, Hospital
Ramo´n y Cajal, Madrid, Spain). Heterogeneity between studies in terms of degree of association was tested using the Q-
statistic.
Results: VDR rs2228570 and rs731236 allelic and genotype frequencies did not differ significantly between MS patients and
controls, and were unrelated with the age of onset of MS, gender, and course of MS. HLADRB1*1501 showed a high
association with the risk of developing MS 4.76(95% C.I. = 3.14–7.27; p,0.0001). The meta-analysis, after excluding data of
one study that was responsible of heterogeneity for rs731236 polymorphism, showed lack of relation of both SNPs with the
risk for MS. HLADRB1*1501 showed lack of interaction with VDR rs2228570 and rs731236 in increasing MS risk.
Conclusions: These results suggest that VDR rs2228570 and rs731236 polymorphisms are not related with the risk for MS,
and did not confirm interaction between these VDR SNPs and HLADRB1 in the risk for MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disorder with axonal degeneration affecting the Central Nervous
system. The etiology of MS is unknown, but likely multifactorial,
with an interplay of genetic, ethnic, geographical and environ-
mental factors (infectious or chemical) [1–5]. Some authors
proposed that MS is an autoimmune disorder with susceptibility
influenced, if not determined, by a relatively small number of
genes [1]. Findings from studies on seasonality in MS patients’
birth, disease onset and exacerbations, as well as apparent
temporal trends in incidence and gender ratio support an
influential effect of viruses, metabolic and lifestyle factors on MS
risk. Epstein-Barr virus, vitamin D status, and smoking are factors
that may explain such epidemiological patterns [4].
A haplotype within the major histocompatibility region is the
major risk factor for MS, but despite clear evidence for a genetic
component additional risk variants were not identified until the
recent advent of genome-wide association studies (GWAS). Until
2010, 11 GWAS have been conducted in MS, and together with
follow-up studies these have confirmed 16 loci with genome-wide
significance [6,7]. Many of these common risk variants are located
at or near genes with central immunological functions (such as
interleukin 2 and 7 receptors, CD58, CD6, CD40, TNFRSF1A
and others) and the majority are associated with other autoim-
mune diseases [6,7]. A further report of the International Multiple
Sclerosis Genetics Consortium, and a Genome Wide metaanalysis
identified at least 50 loci related with the risk for MS [8,9].
However, all loci except HLA showed modest OR in the range of
1.1–1.3 [10]. In particular the association between multiple
sclerosis (MS) and the HLA-DRB1*15:01 haplotype has been
proven to be strong.
In the last years, investigators have paid attention to a possible
role of vitamin D in the etiology of MS [11]:
(A) Several epidemiological studies suggested association be-
tween low 25-hydroxyvitamin D levels and increased MS
risk and, on the other hand, MS risk was lower among
women whose mothers, while pregnant, had increased
vitamin D intake, and among women who had received
vitamin D supplements in adolescence.
(B) Some longitudinal studies showed association between high
25-hydroxyvitamin D levels and lower relapse rates in
patients with MS.
(C) Administration of calcitriol could prevent and slow
progression of experimental allergic encephalomyelitis
(EAE), and vitamin D3 could have a beneficial effect on
EAE severity in female mice. On the other hand, vitamin D
deficiency could reduce EAE severity in mice whose
mothers were vitamin D deficient.
(D) Vitamin D seems to regulate some MS-associated genes,
including the HLA-DRB1*15:01 [12].
(E) CYP27B1, a gene related with vitamin D metabolism, has
been reported among the new genes associated with MS
risk.
Several case-control studies on vitamin D-related genes and MS
risk have been conducted [11,13]. The two most common single
nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR)
gene in Caucasian subjects, rs2228570 (Fok1, formerly
rs10735810) and rs731236 (Taq1), have been the most widely
studied, with inconsistent results. Two case-control studies showed,
respectively, decreased risk for MS related with homozygosis for
the minor allele of rs2228570 [14], and with homozygosis for the
minor allele of rs731236 [15], while other showed increased risk
related with the minor allele of rs731236 [16]. Five case-control
studies showed lack of direct association between rs2228570 and
MS risk [15–19], while other 6 studies showed lack of direct
association between rs731236 and MS risk [14,18,20–23]. Finally,
Cox et al. [19] reported a weak evidence of an association between
the rs731236C allele and MS when combining data on 1153 trio
families and 726 cases and 604 controls, although the study of
cases vs. controls showed a modest increase in MS risk related with
the minor allele.
Figures 1a and b represent the results of the diagnostic ORs and
the 95% confidence intervals(CI) of the studies and the pooled
sample, which showed a lack of association of rs2228570 and
rs731236 with the risk for MS. Q-statistic showed that studies
analyzing both VDR alleles were homogeneous(Q = 8.89,
p = 0.180 and Q_ = 15.61, p 0 0.076; respectively).
Simon et al. [15] reported a significant interaction between
vitamin D intake and rs2228570 polymorphism (80% of decreased
risk of MS for an increase of 400 IU/day of vitamin D in patients
homozygous for the minor allele). Agliardi et al. [22] reported
decreased MS risk for rs731236TT genotype in HLA-DRB1*15
positive individuals, and Cox et al. [19] reported a trend for
increasing risk of MS in subjects who were homozygous for the
HLADRB1*1501 (rs3135388) allele in association with rs2228570.
Orton et al. [24], in a family based study (3037 subjects from
739 families; 1360 of which were affected) reported lack of direct
association of rs731236 and rs2228570 with MS risk, but they
described that HLA-DR15 negative subjects showed over-trans-
mission of the rs2228570T allele. Finally, a meta-analysis of case-
control studies showed a trend toward increased risk for MS for
the dominant model of the rs731236 SNP and lack of relation of
rs2228570 SNP with MS risk [13].
In an attempt to identify additional factors involved in MS
susceptibility, we genotyped the SNPs rs731236 and rs2228570 in
the VDR gene in Spanish Caucasian patients with MS and in
healthy subjects. In addition, we have conducted a meta-analysis
with the available data of previous reports on the same issue.
Despite VDR polymorphisms are not mentioned among the
possible susceptibility genes in GWAS studies, the possible role of
vitamin D in the pathogenesis of MS suggests that VDR gene
should be a candidate gene for modifying MS risk.
As a secondary objective, to address the possible interactions
between VDR genes and HLADRB1*1501, as suggested by
previous reports [19,22,23], we genotyped the SNP
HLADRB1*1501 (rs3135388).
Methods
Patients and controls
We recruited 303 unrelated Caucasian Spanish patients who
fulfilled the McDonald’s criteria for definite MS [25] (94 men, 209
women, mean age 43.9611.4 years, mean age at onset
32.8610.9 years; 164 relapsing-remitting, 94 secondary progres-
sive, and 45 primary progressive MS; mean 6 SD expanded
disability status scale or EDSS 4.762.2), with no other previous
neurological diseases. Recruiting sources were the following: the
‘‘Multiple Sclerosis Association of Madrid’’; n = 170 cases), the
Health Areas of the Hospital La-Mancha-Centro (Alca´zar de San
Juan, Ciudad Real; n = 70 cases), and University Hospitals ‘‘Doce
de Octubre’’ (Madrid, 32 cases), and ‘‘Prı´ncipe de Asturias’’
(Alcala´ de Henares, Madrid; n = 31 cases). The control group was
composed of 310 healthy unrelated Caucasian Spanish individuals
gender and age-matched with the patients (98 men, 212 women;
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mean age 43.4611.7 years), most of them students or staff from
the University of Extremadura.
Ethics statement
All the participants were included in the study after giving
written informed consent. This study was approved by the Ethics
Committee of the University Hospital ‘‘Prı´ncipe de Asturias’’,
University of Alcala´, (Carretera de Alcala´ Meco s/n, Alcala´ de
Henares E28805 Spain). The study was conducted according to
the principles expressed in the declaration of Helsinki.
Genotyping of VDR and HLADRB1 polymorphisms
Genomic DNA was obtained from peripheral leukocytes and
purified according to standard procedures. Two common
polymorphisms in the VDR gene (chromosome 12q12q-14; gene
ID: 7421, OMIM 604311) were analyzed. These SNPs were
selected on the basis of allele frequencies in Caucasian subjects
and were the SNP rs2228570, which causes the amino acid
substitution (Met 1 Thr), and the synonymous SNP rs731236,
which does not cause amino acid substitution (Ile 352 Ile), but it
has been studied with regard to several clinical conditions.
Besides the SNPs analyzed, no other nonsynonymous SNPs
occur in Caucasian individuals.
Table 3. HLADRB1*1501 (rs3135388) genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers.
GENOTYPES ALLELES
rs3135388 T/T rs3135388 T/A rs3135388 A/A rs3135388 T rs3135388 A
MS PATIENTS (N=303,
606 alleles)
184(60.7; 55.2–66.2) 110(36.3; 30.9–41.7) 9(3.0; 1.1–4.9) 478(78.9; 75.6–82.1) 128(21.1; 17.9–24.4)
CONTROLS (N=310,
620 alleles)
278(89.7; 86.3–93.1) 31(10.0; 6.7–13.3) 1(0.3; 0.23–1.0) 587(94.7; 92.9–96.4) 33(5.3; 3.6–7.1)
Intergroup comparison
values OR (95% CI); P.
0.18(0.11–0.28); ,0.0001. 5.13(3.24–8.16); ,0.0001. 9.46(1.22–200.64); 0.010 0.21(0.14–0.32); ,0.0001. 4.76(3.141–7.27); ,0.0001.
MS WOMEN (N=209,
418 alleles)
123(58.9; 52.2–65.5) 82(39.2; 32.6–45.9) 4(1.9; 0.1–3.8) 328(78.5; 74.5–82.4) 90(21.5; 17.6–25.5)
CONTROL WOMEN
(N=212, 424 alleles)
190(89.6; 85.5–93.7) 21(9.9; 5.9–13.9) 1(0.5; 0.25–1.4) 401(94.6; 92.4–96.7) 23(5.4; 3.3–7.6)
Intergroup comparison
values OR (95% CI); P.
0.17(0.10–0.29); ,0.0001. 5.87(3.36–10.33); ,0.0001 4.11(0.43–97.56); 0.173 0.21(0.13–0.35); ,0.0001 4.78(2.98–7.97); ,0.0001
MS MEN (N=94, 188
alleles)
61(64.9; 55.2–74.5) 28(29.8; 20.5–39.0) 5(5.3; 0.8–9.9) 150(79.8; 74.0–85.5) 38(20.2; 14.5–26.0)
CONTROL MEN (N=98,
196 alleles)
88(89.8; 83.8–95.8) 10(10.2; 4.2–16.2) 0(0.0; 0.0–0.0) 186(94.9; 91.8–98.0) 10(5.1; 2.0–8.2)
Intergroup comparison
values OR (95% CI); P.
0.21(0.09–0.49); ,0.0001 3.73(0.16–8.89); 0.001 –; 0.021 0.21(0.10–0.46); ,0.0001 4.71(2.17–10.47); ,0.0001
The values in each cell represent: number (percentage; 95% confidence intervals CI).
doi:10.1371/journal.pone.0065487.t003
Table 4. HLADRB1*1501 (rs3135388) genotypes and allelic variants in patients with MS, and relation with the evolutive type of MS.
GENOTYPES ALLELES
rs3135388 T/T rs3135388 T/A rs3135388 A/A rs3135388 T rs3135388 A
RELAPSING-REMITTING MS
(N=164; 328 alleles)
98(59.8; 52.3–67.3) 62(37.8; 30.4–45.2) 4(2.4; 0.1–4.8) 258(78.7; 74.2–83.1) 70(21.3; 16.9–25.8)
Comparison with control
subjects. OR (95% CI); P.
0.17(0.10–0.28);
,0.0001
5.47(3.28–9.18);
,0.0001
7.73(0.81–183.04);
0.032
0.21(0.13–0.33);
,0.0001
4.83(3.05–7.67);
,0.0001
SECONDARY PROGRESSIVE
MS (N=94; 188 alleles)
58(61.7; 51.9–71.5) 33(35.1; 25.5–44.8) 3(3.2; 0.24–6.7) 149(79.3; 73.5–85.1) 39(20.7; 14.9–26.5)
Comparison with control
subjects. OR (95% CI); P.
0.19(0.10–0.33);
,0.0001
4.87(2.67–8.89);
,0.0001
10.19(0.93–257.32);
0.014
0.22(0.13–0.36);
,0.0001
4.66(2.75–7.88);
,0.0001
PRIMARY PROGRESSIVE MS
(N=45; 90 alleles)
28(62.2; 48.1–76.4) 15(33.3; 19.6–47.1) 2(4.4; 21.–6–10.5) 71(78.9; 70.5–87.3) 19(21.1; 12.7–29.5)
Comparison with control
subjects. OR (95% CI); P.
0.19(0.89–0.41);
,0.0001
4.50(2.05–9.82);
,0.0001
14.37(0.99–409.67);
0.005
0.21(0.11–0.41);
,0.0001
4.76(2.46–9.18);
,0.0001
ALL CONTROLS (N=310, 620
alleles)
278(89.7; 86.3–93.1) 31(10.0; 6.7–13.3) 1(0.3; 0.23–1.0) 587(94.7; 92.9–96.4) 33(5.3; 3.6–7.1)
The values in each cell represent: number (percentage; 95% confidence intervals).
doi:10.1371/journal.pone.0065487.t004
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VDR genotyping was carried out by means of custom TaqMan
Assay (Applied Biosciences Hispania, Alcobendas, Madrid, Spain)
designed to detect the SNPs rs2228570 (C__12060045_20) and
rs731236 (C__2404008_10). HLADRB1*1501 polymorphism was
analyzed with the tagging SNP rs3135388 by using a custom
TaqMan Assay (Applied Biosciences Hispania, Alcobendas,
Madrid, Spain). The detection was carried out by qPCR in an
Eppendorf realplex thermocycler by using fluorescent probes. The
amplification conditions were as follows: After a denaturation time
of 10 min at 96uC, 45 cycles of 92uC 15 sec 60uC 90 sec were
carried out and fluorescence was measured at the end of every
cycle and at endpoint. All samples were determined by triplicate
and genotypes were assigned both, by the gene identification
software (RealPlex 2.0, Eppendorf) and by analysis of the reference
cycle number for each fluorescence curve, calculated by the use of
CalQPlex algorithm (Eppendorf). For technical validation pur-
poses, the amplified fragments for twenty individuals carrying
every genotype (TT, CT and CC for rs2228570 and rs731236 and
TT, AT and all carriers of the AA genotype (n = 10 in the whole
case/control data set) for rs3135388 were sequenced, and in all
cases the genotypes fully corresponded with those detected with
fluorescent probes.
Statistical analysis
The intergroup comparison values were calculated by using the
chi-square or Fisher tests when appropriate. The 95% confidence
intervals were also calculated. The negative predictive value was
calculated as d/r2 (d = number of control individuals with the risk
factor absent; r2 = sum of patients and controls with the risk factor
absent). The Hardy-Weinberg equilibrium was confirmed by
means of Arlequin software Ver. 2.000.
The sample size was determined from allele frequencies
reported for South-European Caucasian individuals as described
elsewhere [26], with a genetic model analyzing the frequency the
Table 5. Gene-gene interaction between the HLA-DRB1*1501 tagging SNP (rs3135388), and the VDR gene polymorphisms in
patients with MS.
rs3135388 (HLADRB1*1501) rs2228570 (VDR Fok1)
Patients Frequency:
N(%; 95% CI)
Controls Frequency:
N(%; 95% CI)
Intergroup comparison
values. OR (95% CI); P. NPV
(95% CI)
T/T A/A 22(12.0; 7.3–16.7) 37(13.4; 9.4–17.4) 0.89(0.49–1.61); 0.675. 0.60(0.58–
0.62)
T/T A/G 83(45.4; 38.1–52.6) 111(40.1; 34.3–45.8) 1.24(0.84–1.84); 0.262. 0.62(0.58–
0.66)
T/T G/G 78(42.6; 35.5–49.8) 129(46.6; 40.7–52.4) 0.85(0.58–1.26); 0.405. 0.59(0.54–
0.63)
A/T A/A 8(7.3; 2.4–12.1) 4(12.9; 1.1–24.7) 0.53(0.13–2.28); 0.323. 0.21(0.18–
0.23)51
A/T A/G 51(46.4; 37.0–55.7) 12(38.7; 21.6–55.9) 1.36(0.57–3.34); 0.451. 0.24(0.18–
0.30)
A/T G/G 51(46.4; 37.0–55.7) 15(48.4; 30.8–66.0) 0.92(0.39–2.20); 0.842. 0.21(0.15–
0.28)
A/A A/A 2(22.2; 24.29–49.4) 0(0.0; 0.0–0.0) –; 0.617. 0.13(0.01–0.13)
A/A A/G 6(66.7; 35.9–97.5) 1(100.0; 100.0–100.0) –; 0.513. 0.0(0.0–0.32)
A/A G/G 1(11.1; 29.24–31.6) 0(0.0; 0.0–0.0) –; 0.739.(0.11(0.10–0.11)
rs3135388 (HLADRB1*1501) rs731236 (VDR Taq1)
Frequency:
N(%; 95% CI)
Controls Frequency:
N(%; 95% CI)
Intergroup comparison
values. OR (95% CI); P. NPV
(95% CI)
T/T T/T 79(43.2; 36.0–50.3) 118(42.6; 36.8–48.4) 1.02(0.69–1.52); 0.904. 0.61(0.56–
0.65)
T/T C/T 81(44.3; 37.1–51.5) 129(46.6; 40.7–52.4) 0.91(0.62–1.35); 0.627. 0.59(0.55–
0.64)
T/T C/C 23(12.6; 7.8–17.4) 30(10.8; 7.2–14.5) 1.18(0.64–2.19); 0.568. 0.61(0.59–
0.62)
A/T T/T 44(40.0; 30.8–49.2) 13(41.9; 24.6–59.3) 1.4(0.63–3.30); 0.351. 0.30(0.24–
0.35)
A/T C/T 46(41.8; 32.6–51.0) 15(48.4; 30.8–66.0) 0.77(0.32–1.84); 0.516. 0.20(0.14–
0.26)
A/T C/C 20(18.2; 11.0–25.4) 3(9.7; 0.27–20.1) 2.07(0.53–9.50); 0.259. 0.24(0.20–
0.26)
A/A T/T 6(66.7; 35.9–97.5) 1(100.0; 100.0–100.0) –; 0.513. 0.0(0.0–0.32)
A/A C/T 2(22.2; 24.29–49.4) 0(0.0; 0.0–0.0) –; 0.617. 0.13(0.01–0.13)
A/A C/C 1(11.1; 29.24–31.6) 0(0.0; 0.0–0.0) –; 0.739. 0.11(0.01–0.11)
NPV negative predictive value.
Combinations for all genotypes were analyzed in 302 MS patients and 309 controls. The frequencies shown correspond to the frequencies of a particular combination of
VDR genotype within every rs3135388 (HLADRB1*1501) genotype category.
doi:10.1371/journal.pone.0065487.t005
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disease gene frequency with a RR value = 1.5, (P = 0.05). The
statistical power for one-tailed and two-tailed associations calcu-
lated for the sample size and allele frequencies observed in this
study is, 96.3% and 92.4% for the VDR SNP rs2228570, 96.4%
and 93.1% for the VDR SNP rs731236 and 53.3% and 40.8% for
the HLADRB1*1501 polymorphism rs3135388.
Haplotype reconstruction was performed using the program
PHASE v2.1.1. We used the default model for recombination rate
variation with 1000 iterations, 500 burn-in iterations and a
thinning interval of 1.
Diplotypes were obtained from the combination of haplotypes
in the best run (the one that showed the maximum consistency of
results across all runs), further details are described elsewhere
[27].
Meta-analysis
All studies that investigated the association of the VDR
rs2228570 and rs731236 polymorphisms with the development
of MS published in any language up to 31 December 2012 and
included in the PubMed database were considered. Search
strategy used the keywords combinations of ‘‘rs2228570 and
multiple sclerosis’’, ‘‘rs731236 and multiple sclerosis’’, ‘‘vitamin D
and multiple sclerosis’’ and ‘‘vitamin D receptor and HLADRB1
and multiple sclerosis’’. From each study, information on the
number of cases and controls for each VDR rs2228570 and
rs731236 genotypes was extracted, and allele frequencies were
calculated. Due to possible statistical inconsistencies and design
differentiations between the studies, the significance of the
association between the alleles of VDR rs2228570 and VDR
rs731236 and risk of having MS was tested for each study. All
associations were indicated as odds ratios (OR) with the
corresponding 95% confidence interval (CI). Based on individual
ORs, fixed effects pooled OR and random effects pooled OR were
estimated. Meta-analysis of case–control studies was carried out by
using the software Meta-DiSc 1.1.1 (http://www.hrc.es/
investigacion/metadisc.html; Unit of Clinical Statistics, Hospital
Ramo´n y Cajal, Madrid, Spain) [28]. The global diagnostic OR
was calculated with the Mantel-Haenszel [29] method when no
heterogeneity was observed. If statistically significant heterogeneity
existed, then the global diagnostic OR was calculated with the
DerSimonian-Laird method [30]. Heterogeneity between studies
in terms of degree of association was tested using the Q-statistic,
Table 6. Case-control studies on VDR rs2228570 (Fok1) and risk for MS (NA = data not available).
AUTHORS [REF] GROUP (N) GENOTYPE FF GENOTYPE Ff GENOTYPE ff ALLELE F ALLELE f
Partridge et al. [14] MS(406) 155(0.382) 196(0.483) 55(0.135) 506(0.623) 306(0.377)
Controls(234) 83(0.355) 105(0.449) 46(0.196) 271(0.579) 197(0.421)
OR(95% CI), p 1.12(0.79–1.60), 0.495 1.15(0.82–1.61), 0.406 0.64(0.41–1.01), 0.041 1.20(0.95–1.53),
0.120
0.83(0.66–1.06),
0.120
Tajouri et al. [16] MS(98) 47(0.480) 40(0.408) 11(0.112) 134(0.684) 62(0.316)
Controls(93) 34(0.365) 48(0.516) 11(0.118) 116(0.624) 70(0.376)
OR(95% CI), p 1.60(0.86–2.98), 0.112 0.65(0.35–1.19), 0.136 0.94(0.36–2.49), 0.896 1.30(0.84–2.04),
0.218
0.77(0.49–1.20),
0.218
Dickinson et al. [18] MS(136) 58(0.426) 61(0.449) 17(0.125) 177(0.651) 95(0.349)
Controls(235) 86(0.366) 110(0.468) 39(0.166) 282(0.600) 188(0.400)
OR(95% CI), p 1.29(0.82–2.03), 0.250 0.92(0.59–1.44), 0.716 0.72(0.37–1.38), 0.289 1.24(0.90–1.72),
0.171
0.81(0.58–1.11),
0.171
Smolders et al. [17] MS(212) 79(0.373) 103(0.486) 30(0.141) 261(0.616) 163(0.384)
Controls(289) 113(0.391) 134(0.464) 42(0.145) 360(0.623) 218(0.377)
OR(95% CI), p 0.93(0.63–1.36), 0.676 1.09(0.75–1.58), 0.624 0.97(0.57–1.66), 0.904 0.97(0.74–1.27),
0.815
1.03(0.79–1.35),
0.815
Simon et al. [15] MS(214) 77(0.360) 96(0.449) 41(0.191) 250(0.584) 178(0.416)
Controls(428) 176(0.411) 188(0.439) 64(0.150) 540(0.631) 316(0.369)
OR(95% CI), p 0.81(0.57–1.15), 0.209 1.04(0.74–1.47), 0.822 1.35(0.86–2.12), 0.175 0.82(0.64–1.05),
0.105
1.22(0.95–1.56),
0.105
Cox et al. [19] MS(727) NA NA NA 886(0.609) 568(0.391)
Controls(604) NA NA NA 748(0.619) 460(0.381)
OR(95% CI), p – – – 0.96(0.82–1.13),
0.603
1.04(0.89–1.22),
0.603
Garcı´a-Martı´n et
al.(Current study)
MS(303) 130(0.429) 141(0.465) 32(0.106) 401(0.662) 205(0.338)
Controls(310) 144(0.465) 124(0.400) 42(0.135) 412(0.665) 208(0.335)
OR(95% CI), p 0.87(0.62–1.21), 0.378 1.31(0.94–1.82), 0.103 0.75(0.45–1.26), 0.257 0.99(0.77–1.26),
0.917
1.01(0.79–1.29),
0.917
TOTAL SERIES MS(2096) 546/1369(0.399) 637/1369(0.465) 186/1369(0.136) 2615(0.624) 1577(0.376)
Controls(2193) 636/1589(0.400) 709/1589(0.446) 244/1589(0.153) 2729(0.622) 1657(0.377)
OR (95% CI), p 0.99(0.86–1.16), 0.937 1.08(0.93–1.25), 0.298 0.87(0.70–1.07), 0.174 1.01(0.92–1.10),
0.879
0.99(0.91–1.09),
0.879
doi:10.1371/journal.pone.0065487.t006
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Table 7. Case-control studies on VDR rs731236 (Taq1) and risk for MS (NA = data not available).
AUTHORS [REF]GROUP (N) GENOTYPE TT GENOTYPE Tt GENOTYPE tt ALLELE T ALLELE t
Partridge et al.
[14]
MS(402) 140(0.348) 203(0.505) 59(0.147) 483(0.601) 321(0.399)
Controls(231) 86(0.372) 106(0.459) 39(0.169) 278(0.602) 184(0.398)
OR(95% CI), p 0.90(0.63–1.28), 0.544 1.20(0.86–1.69), 0.264 0.85(0.53–1.35), 0.460 1.00(0.78–1.27),
0.973
1.00(0.79–1.28),
0.973
Tajouri
et al. [16]
MS(104) 27(0.260) 57(0.548) 20(0.192) 111(0.534) 97(0.466)
Controls(93) 42(0.452) 40(0.430) 11(0.118) 124(0.667) 62(0.333)
OR(95% CI), p 0.43(0.22–0.81), 0.005 1.61(0.88–2.94), 0.099 1.78(0.75–4.25), 0.155 0.58(0.37–0.88),
0.007
1.75(1.14–2.69),
0.007
Dickinson et al.
[18]
MS(136) 52(0.382) 68(0.500) 16(0.118) 172(0.632) 100(0.368)
Controls(235) 86(0.366) 108(0.459) 41(0.175) 280(0.596) 190(0.404)
OR(95% CI), p 1.07(0.68–1.70), 0.753 1.18(0.75–1.84), 0.453 0.63(0.32–1.22). 0.144 1.17(0.85–1.61),
0.325
0.86(0.62–1.18),
0.325
Smolders et al.
[20]
MS(212) 83(0.391) 96(0.453) 33(0.156) 262(0.618) 162(0.382)
Controls(289) 112(0.388) 138(0.477) 39(0.135) 362(0.626) 216(0.374)
OR(95% CI), p 1.02(0.70–1.49), 0.928 0.91(0.63–1.31), 0.585 1.18(0.70–2.01), 0.514 0.97(0.74–1.26),
0.787
1.04(0.79–1.35),
0.787
Simon
et al. [15]
MS(214) 86(0.402) 107(0.500) 21(0.098) 279(0.652) 149(0.348)
Controls(428) 154(0.360) 205(0.479) 69(0.161) 513(0.599) 343(0.401)
OR(95% CI), p 1.20(0.84–1.70), 0.300 1.09(0.77–1.53), 0.616 0.57(0.33–0.98), 0.030 1.25(0.98–1.61),
0.068
0.80(0.62–1.02),
0.068
Sioka et al. [21] MS(69) 30(0.435) 30(0.435) 9(0.130) 90(0.652) 48(0.348)
Controls(81) 33(0.408) 36(0.444) 12(0.148) 102(0.630) 60(0.370)
OR(95% CI), p 1.12(0.55–2.26), 0.736 0.96(0.48–1.93), 0.906 0.86(0.31–2.39), 0.756 1.10(0.67–1.82),
0.686
0.91(0.55–1.50),
0.686
Agliardi
et al. [22]
MS(641) 219(0.342) 308(0.480) 114(0.178) 746(0.582) 536(0.418)
Controls(558) 220(0.394) 249(0.446) 89(0.160) 689(0.617) 427(0.383)
OR(95% CI), p 0.80(0.63–1.02), 0.059 1.15(0.91–1.45), 0.236 1.14(0.83–1.56), 0.398 0.86(0.73–1.02),
0.077
1.16(0.98–1.37),
0.077
Cox et al. [19] MS(727) NA NA NA 843(0.580) 611(0.420)
Controls(604) NA NA NA 749(0.620) 459(0.380)
OR(95% CI), p – – – 0.85(0.72–0.99),
0.035
1.18(1.01–1.39),
0.035
Irı´zar et al. [23] MS(136) 55(0.404) 70(0.515) 11(0.081) 180(0.662) 92(0.338)
Controls(337) 145(0.430) 157(0.466) 35(0.140) 447(0.663) 227(0.337)
OR(95% CI), p 0.90(0.59–1.38), 0.607 1.22(0.80–1.85), 0.337 0.76(0.35–1.61), 0.446 0.99(0.73–1.35),
0.966
1.01(0.74–1.37),
0.966
Garcı´a-Martı´n
et al.(Current
study)
MS(303) 129(0.426) 129(0.426) 45(0.148) 387(0.639) 219(0.361)
Controls(310) 131(0.423) 144(0.464) 35(0.113) 406(0.655) 214(0.345)
OR(95% CI), p 1.01(0.73–1.41), 0.937 0.86(0.61–1.19), 0.335 1.37(0.83–2.26), 0.191 0.93(0.73–1.19),
0.552
1.07(0.84–1.37),
0.552
TOTAL SERIES MS(2944) 821/1396(0.370) 1068/1149(0.482) 328/1889(0.148) 3553(0.603) 2335(0.397)
Controls(3166) 1009/1553(0.394) 1183/1379(0.462) 370/2192(0.144) 3950(0.624) 2382(0.376)
OR(95% CI), p 0.91(0.80–1.02), 0.095 1.08(0.97–1.22), 0.168 1.03(0.87–1.21), 0.730 0.92(0.85–0.99),
0.021
1.09(1.01–1.17),
0.021
doi:10.1371/journal.pone.0065487.t007
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which is a weighted sum of squares of the deviations of individual
study OR estimates from the overall estimate. When ORs are
homogeneous, Q follows a chi-squared distribution with r-1 (r is
the number of studies) degrees of freedom (d.f.). If P.0.10, then
heterogeneity was considered significant.
In order to ensure the rigor of this current meta-analysis, we
designed and reported it according to the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
statement and the checklist is shown in Table S1 (http://www.
prisma-statement.org).
Results
Current study
The frequencies of VDR rs2228570 (Fok1) and rs731236 (Taq1)
genotypes and allelic variants in patients with MS did not differ from
those of controls (Table 1). The genotype and allele frequencies
between MS patients and healthy subjects were in Hardy-Weinberg’s
equilibrium. Mean age at onset of MS did not differ significantly
between patients carrying VDR rs2228570 (Fok1) A/A (mean 6 SD
= 33.0611.5 years), A/G (mean 6 SD = 32.469.8 years) and G/G
genotypes (mean 6 SD = 38.5624.7 years; p = n.s. for the
comparison of carriers vs non-carriers of variant alleles), and between
patients with genotypes VDR rs731236 (Taq1) T/T (mean 6 SD
= 32.5611.5 years), C/T (mean6 SD = 32.6610,6 years) and C/C
(mean 6 SD = 35.6610.9 years; p = n.s. for the comparison of
carriers vs non-carriers of variant alleles).
The distribution of rs2228570 and rs731236 allelic and
genotype frequencies were not influenced by gender (table 1).
The distribution of the rs2228570 and rs731236 genotype and
allelic frequencies did not differ among the MS phenotypes such as
‘‘relapsing-remiting’’, ‘‘primary progressive’’, and ‘‘secondary
progressive’’ evolutive types of MS, and between each type with
controls (table 2).
We also examined interactions between the VDR SNPs with
the tagging SNP rs3135388 for the HLA-DRB*1501 locus
containing a highly conserved vitamin D responsive element
Figure 1. Diagnostic odds ratios and 95% confidence intervals (CI) for each study and for pooled samples of (1–a) rs2228570 (Fok1)
and (1–b) rs731236 (Taq1).
doi:10.1371/journal.pone.0065487.g001
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[19]. Table 3 shows that the rs3135388 SNP has a high
association with the risk of developing MS, with an OR for
carriers of variant alleles equal to 4.76(95% C.I. = 3.14–7.27;
p,0.0001), with a significant gene dose effect according the
Armitage’s test for trend with the number of variant alleles (Chi-
square = 67.61; p,0.0001). Tables 3 and 4 show that the
association of the SNP rs3135388 with the risk of developing
MS, is independent of the gender and of the evolutive type of
the disease. The rs3135388 genotype and allele frequencies
between MS patients and healthy subjects were in Hardy-
Weinberg’s equilibrium. Mean age at onset of MS did not differ
significantly between patients carrying rs3135388 T/T (mean 6
SD = 33.2611.3 years), A/T (mean 6 SD = 32.3610.7 years)
and A/A genotypes (mean 6 SD = 31.364.0 years; p = n.s. for
the comparison of carriers vs non-carriers of variant alleles).
Although the sample size is insufficient to detect weak gene-gene
interactions with a high statistical power, we observed no
significant differences in gene-gene combination frequencies
(Table 5) when we analyzed the interaction between the HLA-
DRB1*1501 tagging SNP (rs3135388), and the VDR gene
polymorphisms, as described elsewhere [19].
Metaanalysis
We identified, including the current study, 7 studies analyzing
the influence of the SNP rs2228570 (2096 MS patients and 2193
controls), and 10 studies on the influence of the SNP rs731236
(2944 MS patients and 3166 controls) and the risk for MS. Data on
these studies, including the genotype and allelic frequencies of the
rs2228570 and rs731236, are showed in Tables 6 and 7,
respectively.
Discussion
The possible role of vitamin D in the pathogenesis of MS makes
reasonable to analyse the possible relationship of VDR polymor-
phisms and gene allelic variants with the risk of MS. In fact,
several studies found direct association of MS risk with the SNPs
VDR rs2228570 [14–16] and rs731236 [19], respectively. More-
over, some studies showed modification of the MS risk related with
the interaction of rs2228570 with vitamin D intake [15] or with
HLA-DR15 [24] or with the interaction of rs731236 with HLA-
DRB1 [19,22,23].
In the present study, we found no significant differences either
in the frequencies of rs2228570 and rs731236 genotypes, or in the
frequencies of the allelic variants of these polymorphisms in
patients with MS. In addition the frequencies for the polymor-
phisms analyzed were neither related with the age at onset of MS,
or with the evolutive type of MS. However, the present study has
some limitations. First, the size of analyzed cohorts may not be
sufficient for strict conclusions about VDR role in MS, and
individual studies of small number of patients gave very
contradictory results. Second, despite the sample size is adequate
to detect an OR as small as 1.5, a more modest association would
not be detected (this is a usual weakness of genetic association
studies). Third, because the cohort study included MS patients
with different degrees of severity, it is not adequate for the
investigation of the influence of VDR genotypes on the disability or
severity of MS (the ideal study for this purpose should include
genotyping of patients with a recent diagnosis of MS with similar
follow-up periods).
The results of the current study regarding rs2228570 are in
agreement with those of other previous case-control studies [15–
19], In contrast, Partridge et al. [14] reported a modest decrease in
the risk for MS in homozygous for the minor allele, but the global
minor allele frequencies of MS patients did not differ significantly
between their MS patients and controls. As should be expected,
the results of the meta-analysis, including the previous and the
current study, confirmed the lack of association between
rs2228570 and MS risk.
The results of the current study regarding rs731236 are in
agreement with other 6 studies [14,18,20–23], while only three
previous reports showed modification of MS risk related with this
SNP. Tajouri et al. [16], in a study including 104 MS patients
and 93 controls, reported increased risk for minor allele carriers
with an odds-ratio of 1.75(1.14–2.69), although this result should
be related with a higher minor allele frequency in MS patients
than that described in other series. In contrast, the report by
Simon et al. [15], which included 212 MS patients and 289
controls, showed a modest decrease in MS risk in homozygous
for the minor allele, with an odds-ratio of 0.57(0.33–0.98), while
the differences in the minor allele frequencies between MS
patients and controls did not reach statistical significance. Finally,
the report by Cox et al. [19], which included 727 MS patients
and 604 controls, showed a modest decrease in MS risk for
minor allele carriers, with and OR of 1.18(1.01–1.39), a finding
that they also found when they analyzed the combined their
case-control and trio family datasets.
The results of the meta-analysis of previous and current studies
on VDR rs2228570 and rs731236 indicate a lack of association of
rs2228570 and rs731236 with the risk for MS, in spite of the
marginal statistical significance of the crude pooled values for
rs731236 shown in Table 7. This apparent discrepancy is related
to the use of the DerSimonian-Laird method for the calculation of
the diagnostic OR. This method is more restrictive than the
Mantel-Haenszel method that gives the same results as shown in
Table 7 (P = 0.029).
In the present study, we confirmed the previously described
association between HLADRB1*1501 (rs3135388) haplotype and
the risk of developing MS. On the other hand, we did not find
association between the interaction of rs2228570 and rs731236
SNPs with HLADRB1*1501 haplotype and MS risk. The
comparison with other studies addressing this issue is difficult
taking in account the data reported because the heterogeneity of
both the methodology and the results:
(A) The first study, reported by Orton et al. [24] was not a case-
control study, but a family based study, described a modest
increased MS risk in HLA-DR15 negative subjects carrying
the rs2228570T allele, and found no significant interaction
between rs731236 and the risk for MS.
(B) Agliardi et al. [22], in a case-control including 187 MS
patients and 197 controls HLA-DRB1*15-positive and 454
MS patients and 363 controls HLA-DRB1*15-negative,
found a modest decrease in the risk for MS in HLA-
DRB1*15-positive subjects carrying the rs731236TT geno-
type or the rs731236T allele. They also described lack of
interaction between HLA-DRB1 and rs2228570 and
rs1989969 SNPs and the risk for MS.
(C) Cox et al. [19], using the combination of a case-control
cohort including 727 MS patients and 604, and 1153 trio
families(MS patient and both parents), found a trend
towards increased r i sk for sub jec t s car ry ing
rs3135388AA and rs2228570CC genotypes, with an
OR of 7.198(2.62–19.78), and for subjects carrying
rs3135388 AA and rs731236CC genotypes, with an
OR of 3.014(2.019–4.498), all of them compared with
subjects with TT genotypes for both SNPs). However,
Vitamin D3 Receptor and Multiple Sclerosis
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data regarding genotype and allele distribution are not
given.
(D) Irı´zar et al. [23] reported a non-significant trend towards
increased risk for MS in HLA-DRB1*15-positive subjects
carrying rs7975232A or rs731236T alleles in a case-control
study which included 325 HLA-DRB1*15-positive subjects
(96 MS patients and 229 controls) and 110 HLA-DRB1*15-
negative subjects (34 MS and 76 controls) genotyped for
rs7975232, and 392 HLA-DRB1*15-positive subjects (122
MS patients and 270 controls) and 43 HLA-DRB1*15-
negative subjects (11 MS and 32 controls) genotyped for
rs731236.
In summary, the results of the present study, taken together
with those of the meta-analysis, suggest that rs2228570 and
rs731236 genotype and allelic variants are not related with the
risk for MS. In addition, although this study confirmed the
association between rs3135388 SNP and the risk for MS, the
previously suggested interaction between HLADRB1 and the two
studied SNPs in the VDR gene in the risk of developing MS was
not confirmed.
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